MDM2 and breast carcinoma: To confirm that the effect of MDM2 silencing is unequivocally related to GATA3 loss of function and to exclude any gain-of-function effects of the GATA3 mutation, we assessed the changes in cell proliferation upon single- and dual-silencing of GATA3 and MDM2 using siRNA in two ER-positive GATA3-wild type breast cancer cell lines, the luminal A (ER+/HER2−) MDA-MB134 and the luminal B (ER+/HER2+) BT-474 (Supplementary Fig. 1d, e).